Advanced

Modulation of cGMP-signalling to Prevent Retinal Degeneration

Marigo, Valeria; Ekström, Per LU ; Schwede, Frank; Rentsch, Andreas and Paquet-Durand, François LU (2019) In RSC Drug Discovery Series 2019-January(66). p.88-98
Abstract

In the photoreceptors of the retina, the second-messenger molecule cyclic guanosine monophosphate (cGMP) occupies centre stage in the phototransduction cascade. Remarkably, cGMP is also involved in hereditary photoreceptor degeneration caused by a variety of different genetic insults. This provides an entry point for the development of inhibitory cGMP analogues for a mutation-independent treatment. Here, we outline how cGMP signalling can be targeted for the treatment of retinal degeneration, how inhibitory cGMP analogues may be designed and formulated, and how test systems of rising complexity can be used to identify new compounds with photoreceptor neuroprotective properties. In this context, we cite the European Union-funded... (More)

In the photoreceptors of the retina, the second-messenger molecule cyclic guanosine monophosphate (cGMP) occupies centre stage in the phototransduction cascade. Remarkably, cGMP is also involved in hereditary photoreceptor degeneration caused by a variety of different genetic insults. This provides an entry point for the development of inhibitory cGMP analogues for a mutation-independent treatment. Here, we outline how cGMP signalling can be targeted for the treatment of retinal degeneration, how inhibitory cGMP analogues may be designed and formulated, and how test systems of rising complexity can be used to identify new compounds with photoreceptor neuroprotective properties. In this context, we cite the European Union-funded DRUGSFORD project and provide an example for the efficacy of a specific cGMP analogue to prevent photoreceptor loss and preserve retinal function.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
RSC Drug Discovery Series
volume
2019-January
issue
66
pages
11 pages
external identifiers
  • scopus:85056596719
ISSN
2041-3203
DOI
10.1039/9781788013666-00088
language
English
LU publication?
yes
id
9dc6a528-cc57-4f98-9579-980482c92b22
date added to LUP
2018-11-26 12:53:13
date last changed
2019-01-06 14:17:21
@article{9dc6a528-cc57-4f98-9579-980482c92b22,
  abstract     = {<p>In the photoreceptors of the retina, the second-messenger molecule cyclic guanosine monophosphate (cGMP) occupies centre stage in the phototransduction cascade. Remarkably, cGMP is also involved in hereditary photoreceptor degeneration caused by a variety of different genetic insults. This provides an entry point for the development of inhibitory cGMP analogues for a mutation-independent treatment. Here, we outline how cGMP signalling can be targeted for the treatment of retinal degeneration, how inhibitory cGMP analogues may be designed and formulated, and how test systems of rising complexity can be used to identify new compounds with photoreceptor neuroprotective properties. In this context, we cite the European Union-funded DRUGSFORD project and provide an example for the efficacy of a specific cGMP analogue to prevent photoreceptor loss and preserve retinal function.</p>},
  author       = {Marigo, Valeria and Ekström, Per and Schwede, Frank and Rentsch, Andreas and Paquet-Durand, François},
  issn         = {2041-3203},
  language     = {eng},
  number       = {66},
  pages        = {88--98},
  series       = {RSC Drug Discovery Series},
  title        = {Modulation of cGMP-signalling to Prevent Retinal Degeneration},
  url          = {http://dx.doi.org/10.1039/9781788013666-00088},
  volume       = {2019-January},
  year         = {2019},
}